Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth projections, multiple product launches, and strategic market expansions, which are positive indicators. Although increased expenses for development and some ambiguity in trial details were noted, the overall sentiment remains positive due to optimistic guidance and strategic investments. The Q&A session did not reveal significant concerns that would alter this sentiment.
Key Financial Performance
Total Revenue Grew by 25% year-over-year, driven by strong royalties from DARZALEX and Kesimpta, as well as product sales from proprietary medicines like EPKINLY.
Operating Profit Increased by 23% year-over-year, achieved despite significant investments in EPKINLY, Rina-S, and petosemtamab, reflecting disciplined capital allocation.
Sales for the Quarter Totaled $176 million, representing 43% growth compared to Q1 last year, driven by Tivdak and EPKINLY's performance in new and established markets.
EPKINLY Sales Grew 52% year-over-year, reaching $137 million, driven by its position as the only bispecific approved in DLBCL and FL indications, as well as the approval of fixed duration EPKINLY plus R2 in second-line FL.
Tivdak Sales Grew 18% year-over-year, reaching $39 million, reflecting its position as the global standard of care in recurrent or metastatic cervical cancer and effective commercialization in new markets.
Tax Expense Around $21 million, equating to an effective tax rate of 28.9%. The rate may experience volatility due to the integration of Merus operations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EPKINLY: Continued positive momentum with hospitalization recommendation removed for third-line plus relapse or refractory diffuse large B-cell lymphoma label. Achieved 52% year-over-year growth, reaching $137 million in sales. Expanded utilization in the U.S. and globally, with approvals in over 65 countries. Recent FDA label revision expected to broaden use in outpatient settings.
Rina-S: Significant progress in development with two new Phase III trials planned for ovarian and endometrial cancers. Phase III RAINFOL-02 trial in platinum-resistant ovarian cancer completed enrollment ahead of schedule. Data sets expected in the second half of 2026, supporting potential broader regulatory filings.
Tivdak: Achieved 18% year-over-year growth, reaching $39 million in sales. Expanded commercialization in Japan, Europe, and the U.K., with infrastructure being established in France, Italy, and Spain. Maintains position as the global standard of care in recurrent or metastatic cervical cancer.
Global Expansion: EPKINLY approved in over 65 countries, with strong growth in Japan and Europe. Tivdak expanded into new markets, including the U.K., with preparations for launches in France, Italy, and Spain.
Revenue Growth: Achieved 25% total revenue growth in Q1 2026, driven by strong royalties and product sales, particularly EPKINLY.
Profitability: Operating profit grew by 23%, despite significant investments in late-stage development and commercialization.
Pipeline Development: Focused investments in late-stage assets like Rina-S and petosemtamab, with multiple Phase III trials and launch readiness activities underway.
Integration of Merus: Progressing integration efforts to capture full value of petosemtamab, with tax implications under evaluation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Development Project Delays: Potential delays or unsuccessful development projects could materially impact results, as highlighted in the forward-looking statements.
Integration of Merus: Challenges in integrating Merus operations, including tax-related volatility, could affect financial stability and operational efficiency.
Regulatory Approvals: Dependence on regulatory approvals for product launches in new markets, such as Europe and Japan, poses a risk to growth projections.
Market Competition: Competitive pressures in the oncology market, particularly for products like EPKINLY and Tivdak, could impact market share and revenue growth.
Supply Chain and Site Activation: Delays in site activation and supply chain issues in newer markets could hinder product availability and adoption.
Tax Rate Volatility: Integration activities related to Merus may cause tax rate volatility, potentially impacting financial predictability.
Strategic Investments: Significant investments in late-stage development and launch readiness could strain financial resources if expected returns are not realized.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Rina-S Development: Anticipation of starting two new Phase III trials for Rina-S in the coming months, focusing on ovarian and endometrial cancers. Recruitment for the Phase III RAINFOL-02 trial in platinum-resistant ovarian cancer has been faster than expected, with pivotal data expected in 2026. Two data sets for Rina-S in platinum-resistant ovarian cancer are expected in the second half of 2026, potentially enabling earlier global regulatory filings.
EPKINLY Growth and Development: Focus on maximizing first-mover advantage in second-line FL in the U.S., with expected approvals in Europe and Japan later in 2026. Plans to accelerate development, including combination therapies across early lines of therapy, to establish EPKINLY as a core therapy in B-cell malignancies.
Tivdak Expansion: Plans to expand Tivdak's presence in advanced cervical cancer markets, with infrastructure and teams being established in key European markets such as France, Italy, and Spain. Efforts to secure broader availability in the U.K. through NICE and SMC engagement.
Financial Guidance for 2026: Revenue growth expected at 14%, driven by EPKINLY and royalty portfolio. Operating expenses projected between $2.7 billion and $2.9 billion, reflecting investments in late-stage development and launch readiness. Commitment to maintaining substantial profitability in 2026.
Merus Integration: Integration of Merus operations is ongoing, with tax rate normalization expected within 12 to 18 months. Focus on capturing the full value of petosemtamab.
Long-term Financial Strategy: Targeting gross leverage below 3x by the end of 2027 while maintaining balance sheet strength and flexibility.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the rationale behind the increased size of the frontline petosemtamab head and neck cancer study and its implications?
A:The study size was increased to ensure the highest probability of success based on insights generated during due diligence. The changes are not expected to impact timelines, and the guidance remains that one or both peto studies will read out this year.
Q:Why does the increased size of the first-line trial not impact the timing, given the increase from 500 to 700 patients?
A:The increase was planned to ensure appropriate data for success without impacting timelines. Enrollment is progressing well, and the changes do not affect the timing or accrual status.
Q:Is the EPKINLY first-line DLBCL readout this year a final analysis or an interim?
A:The company has not commented on whether the readout will be interim or final but maintains that the study will read out this year.
Q:Will the Phase II and Phase III Rina-S trials report as separate results, and will the Phase II be filed if positive?
A:The Phase III trial is the main dataset for filing and global submissions. The Phase II and Phase III datasets are supportive, but the Phase III is more relevant for approval.
Q:How does the company view B7-H4 ADCs in gynecological cancers compared to folate ADCs?
A:The company acknowledges the competitive landscape but believes Rina-S has strong data in terms of efficacy, safety, durability, and speed to market, potentially making it best-in-class.
Q:What are the expectations for the EPKINLY frontline DLBCL trial regarding PFS curves and IPI Stage 2 patient caps?
A:The company refrains from speculating on PFS curve behavior and does not disclose demographics. The primary endpoint focuses on IPI 3 to 5, with additional analysis for IPI 2 to 5.
Q:What is the relevant benchmark for EPCORE DLBCL-4 in the second-line trial?
A:The trial compares against R-GemOx, aiming for a patient-friendly regimen suitable for community settings with improved efficacy and safety.
Q:Is the new Rina-S trial, RAINFOL-08, likely to be a KEYTRUDA combination trial?
A:The company has ongoing pembrolizumab cohorts and will communicate data when mature. The combination with bevacizumab has shown good safety and efficacy.
Q:How has enrollment for the EPCORE DLBCL-2 trial progressed, and can the fixed-duration treatment replicate Phase II data?
A:Enrollment has been faster than projected. The fixed-duration treatment is expected to replicate Phase II data due to predictable mechanisms and high MRD negativity rates.
Q:What are the sequencing preferences for drugs in DLBCL, and how does EPKINLY fit in?
A:Physicians prefer bispecifics upfront due to efficacy and safety. EPKINLY's subcutaneous administration and potential to avoid relapsed/refractory settings make it favorable.
Q:What are the expectations for peto Phase II OS rates and Rina-S in second-line endometrial cancer?
A:The company focuses on Phase III data for peto. For Rina-S, the Phase III trial is enrolling well, and the ASCO data shows good durability.
Q:What are the plans for CRC development with peto, and are other mechanisms being explored?
A:The company continues to evaluate CRC data and plans to update on next steps. Combinations with other mechanisms are being considered.
Q:What is the rationale for increasing the peto trial size, and does it focus on HPV-negative patients?
A:The increase aims to enhance the probability of success without impacting timelines. Specific patient breakdowns are not disclosed.
Q:Will the LiGeR program file with both studies or separately, and will OS data be available?
A:The company has not disclosed filing plans or OS data specifics but expects one or more studies to read out this year.
Q:What drives enthusiasm for EPKINLY in the first-line setting?
A:EPKINLY's efficacy, safety, subcutaneous administration, and suitability for community settings drive enthusiasm, along with its potential to be first to read out in frontline DLBCL.
Q:Has the recent label change in the U.S. driven EPKINLY's Q1 performance?
A:Yes, the label change and second-line FL launch have contributed to strong performance, with positive feedback from physicians and health systems.
Q:What PFS hazard ratio is needed for EPCORE DLBCL-2 to be clinically meaningful, and is OS benefit necessary?
A:The company refrains from speculating on hazard ratios. OS benefit is not required for approval but depends on PFS effect size.
Q:Will the peto trial upsizing involve new investigational sites?
A:No, the upsizing will not require additional sites as the study is enrolling well.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the rationale for increasing the peto trial size, patient demographics, and interim versus final analysis for EPKINLY. They also refrained from speculating on PFS hazard ratios, OS data, and specific filing plans for the LiGeR program.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
EPKINLY Rina
III trial
Jan
Phase III
Rina petosemtamab
Rina platinum
UK
ability commercialization
allocation priority
appendix
brand
cancer Tivdak
cancer opportunity
capital allocation
chemo
commercialization market
community
creation
discipline
field site
highlight
hospitalization dose
integration Merus
label
line DLBCL
line FL
medicine patient
momentum portfolio
oncology
opportunity Rina
outpatient
patient market
platinum cancer
presence
priority investment
recommendation
site activation
tax
team market
GMAB Transcript
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call highlights strong revenue growth projections, multiple product launches, and strategic market expansions, which are positive indicators. Although increased expenses for development and some ambiguity in trial details were noted, the overall sentiment remains positive due to optimistic guidance and strategic investments. The Q&A session did not reveal significant concerns that would alter this sentiment.
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript
Positive2-17
The earnings call highlights strong future revenue projections, significant product pipeline developments, and strategic market expansions, which are positive indicators. The Q&A section reveals management's optimism about trial outcomes and market strategies, despite some vagueness in responses. The company's focus on strategic acquisitions and disciplined financial management further supports a positive outlook. However, the lack of interim trial details could cause some uncertainty. Overall, the strong revenue and product potential, combined with strategic growth plans, suggest a positive stock price movement in the short term.
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
GMAB Slides
GMAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
